These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18998350)

  • 1. Can HIV be cured?
    Stevenson M
    Sci Am; 2008 Nov; 299(5):78-83. PubMed ID: 18998350
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS. Boosting immunity to HIV--can the virus help?
    Autran B; Carcelain G
    Science; 2000 Nov; 290(5493):946-9. PubMed ID: 11184735
    [No Abstract]   [Full Text] [Related]  

  • 3. Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation.
    Moreno S; Serrano-Villar S
    EBioMedicine; 2016 Nov; 13():31-32. PubMed ID: 27765640
    [No Abstract]   [Full Text] [Related]  

  • 4. Can immune systems be trained to fight HIV?
    Balter M
    Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of HIV replication by antiretroviral therapy reduces TIM-3 expression on HIV-specific CD8(+) T cells.
    Kassu A; Marcus RA; D'Souza MB; Kelly-McKnight EA; Palmer BE
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):1-3. PubMed ID: 20860535
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.
    Guihot A; Tubiana R; Breton G; Marcelin AG; Samri A; Assoumou L; Goncalves E; Bricaire F; Costagliola D; Calvez V; Rouzioux C; Autran B; Katlama C; Carcelain G; ;
    AIDS; 2010 Feb; 24(4):614-7. PubMed ID: 19952710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells.
    Degen O; Stellbrink HJ; Lauer J; van Lunzen J
    AIDS; 1998 Sep; 12(13):1715-6. PubMed ID: 9764793
    [No Abstract]   [Full Text] [Related]  

  • 8. TFH in HIV Latency and as Sources of Replication-Competent Virus.
    Miles B; Connick E
    Trends Microbiol; 2016 May; 24(5):338-344. PubMed ID: 26947191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
    Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
    AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the body control HIV infection without drugs?
    Check E
    Newsweek; 2000 Oct; 136(15):59. PubMed ID: 11184537
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of HIV despite the discontinuation of antiretroviral therapy.
    Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
    N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intermittent therapy ought to strengthen the immune system].
    Volkert R
    Dtsch Med Wochenschr; 1999 Mar; 124(11):A8. PubMed ID: 10209528
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-HIV drugs work rapidly or not at all. Virus dynamics--therapeutic consequences].
    Aulehla S
    Fortschr Med; 1995 Apr; 113(12):14-6. PubMed ID: 7789929
    [No Abstract]   [Full Text] [Related]  

  • 15. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 16. How does HIV overcome the body's T cell bodyguards?
    Balter M
    Science; 1997 Nov; 278(5342):1399-400. PubMed ID: 9411761
    [No Abstract]   [Full Text] [Related]  

  • 17. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 18. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 19. Poor functional immune recovery in aged HIV-1-infected patients following successfully treatment with antiretroviral therapy.
    Kasahara TM; Hygino J; Andrade RM; Monteiro C; Sacramento PM; Andrade AF; Bento CA
    Hum Immunol; 2015 Oct; 76(10):701-10. PubMed ID: 26429325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.